Literature DB >> 22460755

Prevention of bisphosphonates-induced osteonecrosis.

Anna Baraldi1, Vittorio Fusco, Alessandro Bellora, Massimo Pini.   

Abstract

The osteonecrosis of the jaw is a new emergent disease, secondary to prolonged use of bisphosphonates. Bisphosphonates are a class of drug used in prevention and cure of bone diseases such as malignancy or bone metabolic diseases. In this article, we have tried to summarize, for patients taking IV or oral bisphosphonates-therapy, the most important informations on the pathogenesis and the risk factors in osteonecrosis of the jaw with particular attention about the preventive policies.

Entities:  

Year:  2007        PMID: 22460755      PMCID: PMC2781179     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  38 in total

1.  Bisphosphanates and oral cavity avascular bone necrosis.

Authors:  Cesar A Migliorati
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

Review 2.  Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.

Authors:  Jose V Bagan; Yolanda Jimenez; Judith Murillo; Sergio Hernandez; Rafael Poveda; José M Sanchis; José M Diaz; Crispian Scully
Journal:  Oral Oncol       Date:  2005-11-04       Impact factor: 5.337

3.  Osteonecrosis of the jaw: more research needed.

Authors:  Elizabeth Shane; Steve Goldring; Sylvia Christakos; Marc Drezner; John Eisman; Stuart Silverman; David Pendrys
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

4.  Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?

Authors:  M Ardine; D Generali; M Donadio; S Bonardi; M Scoletta; A M Vandone; M Mozzati; O Bertetto; A Bottini; L Dogliotti; A Berruti
Journal:  Ann Oncol       Date:  2006-03-08       Impact factor: 32.976

5.  Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.

Authors:  Kostas Zervas; Evgenia Verrou; Zisis Teleioudis; Konstantinos Vahtsevanos; Anastasia Banti; Dimitra Mihou; Dimitris Krikelis; Evangelos Terpos
Journal:  Br J Haematol       Date:  2006-08-01       Impact factor: 6.998

6.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

Review 7.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Authors:  Martha Q Lacy; Angela Dispenzieri; Morie A Gertz; Philip R Greipp; Kimberly L Gollbach; Suzanne R Hayman; Shaji Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig; Steven R Zeldenrust; David Dingli; P Lief Bergsagel; Rafael Fonseca; Craig B Reeder; A Keith Stewart; Vivek Roy; Robert J Dalton; Alan B Carr; Deepak Kademani; Eugene E Keller; Christopher F Viozzi; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

8.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

9.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 10.  Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.

Authors:  Franco Capsoni; Matteo Longhi; Roberto Weinstein
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.